When will survodutide be approved? Not in 2026, and most likely not before 2028. Boehringer Ingelheim has finished its phase 3 obesity programme and is moving forward with global regulatory submissions in obesity in 2027, according to Zealand Pharma's report of 12 November 2026. As of 15 November 2026, survodutide is approved nowhere.
The argument of this piece is that survodutide no longer has an efficacy problem or a heart-safety problem, and that its real test is tolerability. On 9 November 2026 the SYNCHRONIZE-CVOT trial showed no increase in major cardiovascular events against placebo, the result Zealand Pharma calls a first for a glucagon and GLP-1 dual agonist. In the same trial, about one person in five on survodutide stopped treatment because of stomach side effects, against 1.9% on placebo. Boehringer's own reply, a set of new trials with slower and more flexible dose escalation, shows the company reads the data the same way. The liver indication, the one with an FDA Breakthrough designation, runs years behind the obesity filing.
Nothing below is medical advice, and this page does not tell anyone whether to take, wait for or switch to any medicine. Doses appear only as the names of trial arms, the way the papers report them. Every date and figure comes from a source read on 15 November 2026 and linked at the foot of the page. The decision dates are our own arithmetic from published FDA review goals, and each one is labelled as arithmetic. Where a figure counts only people who stayed on treatment, the text says so, because those figures always run higher than the ones that count everyone who was randomised.
When will survodutide be approved by the FDA?
Survodutide has no FDA approval date because Boehringer Ingelheim has not yet filed an application, and the FDA review clock starts only at submission. Zealand Pharma, which invented the molecule and licensed it to Boehringer, wrote on 9 November 2026 that the registrational phase 3 SYNCHRONIZE programme in overweight and obesity is complete, and quoted Boehringer as moving forward with global regulatory submissions in obesity. Its nine-month report of 12 November 2026 added the year: 2027. Neither document gives a quarter. A search of Drugs@FDA and of the openFDA drugsfda dataset on 15 November 2026 returned no record for survodutide, which is what an unfiled, unapproved molecule looks like in the FDA's own files.
From the filing, the FDA's published performance goals for fiscal years 2023 to 2027 set the pace. For a new molecular entity, the agency aims to act on 90% of standard applications within ten months of the 60-day filing date, about twelve months after submission, and on priority applications within six months of that date, about eight months after submission. A filing early in 2027 with priority review would point to late 2027. A filing late in 2027 on standard review would point to late 2028. The middle of that range, and the most likely outcome on what is public today, is a decision in 2028. That is our arithmetic, not a date from Boehringer, Zealand or the FDA.
What did the SYNCHRONIZE phase 3 trials show?
The SYNCHRONIZE trials showed that survodutide produces clear weight loss against placebo in four different groups of adults, with stomach side effects as the main cost. The cleanest figure comes from SYNCHRONIZE-1, published in the New England Journal of Medicine: among 725 adults without diabetes, average weight change at 76 weeks, counting everyone randomised, was 12.2% on the 3.6 mg arm and 13.0% on the 6.0 mg arm, against 5.4% on placebo. Boehringer's announcement of 28 April 2026 led with a larger number, up to 16.6% against 3.2%, which counts people only while they stayed on treatment. Both numbers are true. They answer different questions, and the first is closer to what happens in a clinic, where some people stop.
| Trial (published) | Who and how long | Average weight change, everyone randomised | Stopped for stomach side effects |
|---|---|---|---|
| SYNCHRONIZE-1 (NEJM, Jun 2026) | 725 adults without diabetes, 76 weeks | -12.2% (3.6 mg), -13.0% (6.0 mg) vs -5.4% placebo | 19% vs 2.9% |
| SYNCHRONIZE-2 (NEJM, Oct 2026) | 752 adults with type 2 diabetes, 76 weeks | -8.2% (3.6 mg), -9.8% (6.0 mg) vs -3.9% placebo | Not in abstract |
| SYNCHRONIZE-MASLD (Nat Med, Jun 2026) | Adults with fatty liver disease, 48 weeks | Up to -12.2% vs -1.0% placebo (on treatment) | Consistent with SYNCHRONIZE-1, per Boehringer |
| SYNCHRONIZE-CVOT (Lancet, Nov 2026) | 5,530 adults at raised heart risk, median 22 months | Up to -13.7% vs -2.0% placebo at 72 weeks (on treatment) | 19.3% (3.6 mg), 20.8% (6.0 mg) vs 1.9% |
Sources: NEJM and Lancet abstracts on PubMed; Boehringer Ingelheim release of 7 June 2026; Zealand Pharma announcement of 9 November 2026. "On treatment" figures use the efficacy or supplementary estimand and run higher than the everyone-randomised figures. Separate trials with different populations: do not compare rows.
SYNCHRONIZE-2, published online in the New England Journal of Medicine on 1 October 2026, tested the drug in 752 adults with type 2 diabetes, a group that typically loses less weight on any incretin drug. Average weight change at 76 weeks was 8.2% and 9.8% on the two doses against 3.9% on placebo, and glycated haemoglobin fell by 0.9 and 0.8 percentage points from a baseline of 7.4%, against 0.2 on placebo. SYNCHRONIZE-MASLD, published in Nature Medicine, looked at the liver: Boehringer reported that up to 61.0% of participants reached a normal liver fat content at 48 weeks, against 5.7% on placebo. The mechanism behind that liver signal is explained in our piece on glucagon agonism.
The trials settled whether survodutide works. The number that will shape its label is the one in five who stopped taking it.
Is survodutide safe, and why did so many people stop taking it?
Survodutide passed the cardiovascular safety test that regulators expect from a new obesity drug. SYNCHRONIZE-CVOT, published in The Lancet on 9 November 2026, randomised 5,530 adults with obesity and established heart disease, chronic kidney disease or several cardiovascular risk factors, at 524 sites in 34 countries, and followed them for a median of 22 months. The primary composite of cardiovascular death, non-fatal stroke, non-fatal heart attack, coronary revascularisation or heart failure events occurred in 3.7% on survodutide and 4.1% on placebo, a hazard ratio of 0.89 with a confidence interval from 0.67 to 1.18. That rules out the pre-set level of harm. It does not show protection, and the authors do not claim it does.
The same Lancet paper carries the number that matters most for patients. Nausea was reported by 48.0% and 49.0% on the two survodutide arms against 12.1% on placebo, and vomiting by 31.7% and 34.0% against 4.8%. Treatment was stopped for gastrointestinal adverse events by 19.3% on 3.6 mg and 20.8% on 6.0 mg, against 1.9% on placebo, close to the 19% against 2.9% that Boehringer reported for SYNCHRONIZE-1 in June. Zealand's announcement explains the pattern: the original protocols allowed little room to slow the dose increase or pause treatment, so people stopped who might otherwise have continued. Serious adverse events were similar across groups, at 22.5%, 20.8% and 23.9%.
Will survodutide be approved for fatty liver disease (MASH)?
Survodutide is unlikely to reach a liver label before the end of this decade, even though the liver is where its regulatory recognition is strongest. The FDA granted it Fast Track designation in May 2021 and Breakthrough Therapy designation in September 2024 for MASH with moderate or advanced fibrosis, according to Boehringer. Neither designation is an approval, and both apply to the liver indication, not to obesity. The trials that would support a liver approval are LIVERAGE, about 1,800 adults with fibrosis stages 2 or 3, and LIVERAGE-Cirrhosis, about 1,590 adults with compensated cirrhosis. On ClinicalTrials.gov, read on 15 November 2026, both are still recruiting, with estimated primary completion dates of 27 December 2031 and 5 June 2029.
Registry completion dates are sponsor estimates and often move, and liver trials sometimes file on an interim biopsy analysis before the final readout. Boehringer has not said whether LIVERAGE has such an analysis or when it would come. What can be said is that the obesity filing in 2027 does not wait for the liver data, and that any page presenting survodutide as an approved or imminent treatment for fatty liver disease is ahead of the record. For readers following the wider regulatory picture of incretin and peptide drugs, our compound tracker lists what is approved, what is under review and what is only nominated, with a source and a date on every row.
Can you buy survodutide now?
Survodutide cannot legally be sold for human use in the United States today. The FDA's page on unapproved GLP-1 drugs, current as of 1 October 2026, says the agency has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labelled "for research purposes" or "not for human consumption". Survodutide also does not appear in the FDA's list of bulk substances nominated for use in compounding under section 503A, updated 14 May 2026, so pharmacies have no route to prepare it. Search results for survodutide are crowded with vendor pages, and some headlines use the word approval loosely. Our explainer on research-use-only peptides covers what those labels mean and what they do not.
Is the dropout rate really the story, or a protocol artefact?
The strongest objection to this reading is Boehringer's own: that the dropout rate reflects rigid trial protocols, not the molecule. The argument has weight. Every incretin drug causes stomach side effects that peak during dose escalation, and slower titration is the standard way to reduce them. Boehringer has opened trials built to test exactly that, including SYNCHRONIZE-START on real-world titration and switching from GLP-1 drugs, and SYNCHRONIZE-HERA in women's health. The liver data also offer a case for survodutide that does not rest on weight loss alone, which is why the company keeps framing it as a metabolic drug rather than a slimming one.
The objection is incomplete on timing. On ClinicalTrials.gov, SYNCHRONIZE-START is not yet recruiting and lists an estimated primary completion date of 6 November 2029, and SYNCHRONIZE-HERA lists 26 July 2028. A 2027 filing will be judged on the trials that exist, and those show roughly one in five people stopping for stomach side effects on either dose. That number will shape the label, the dosing instructions and the way doctors and insurers compare survodutide with drugs already on the market. It is also why we think the first approval, when it comes, matters less than the titration data that follow it.
So when will survodutide be available, in short?
Survodutide is not approved and not yet filed. Boehringer Ingelheim plans global regulatory submissions in obesity in 2027, and on the FDA's published review goals a decision most likely lands in 2028, by our arithmetic. Phase 3 showed average weight loss of 12.2% to 13.0% at 76 weeks in adults without diabetes, counting everyone randomised, and no increase in major cardiovascular events in 5,530 higher-risk adults. About one in five stopped because of stomach side effects. The liver trials run to 2029 and 2031 on current registry estimates. We will update this page when Boehringer files, when the FDA accepts the application and when a decision date is public. Compare it with the timelines for retatrutide and CagriSema.
Sources
- Zealand Pharma, Company announcement No. 55/2026: SYNCHRONIZE-CVOT results and Boehringer Ingelheim moving forward with global regulatory submissions in obesity, 9 November 2026. www.globenewswire.com
- Zealand Pharma, Financial results for the first nine months of 2026: global regulatory submissions in obesity in 2027, 12 November 2026. www.globenewswire.com
- Boehringer Ingelheim, SYNCHRONIZE-1 topline results, news release, 28 April 2026. www.boehringer-ingelheim.com
- Boehringer Ingelheim, SYNCHRONIZE-1 and SYNCHRONIZE-MASLD full results, news release, 7 June 2026. www.boehringer-ingelheim.com
- le Roux CW et al., Survodutide Once Weekly for the Treatment of Adults with Obesity, N Engl J Med 2026;395:776-787 (SYNCHRONIZE-1). pubmed.ncbi.nlm.nih.gov
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes, N Engl J Med, published online 1 October 2026 (SYNCHRONIZE-2). pubmed.ncbi.nlm.nih.gov
- Bozkurt B et al., Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), Lancet, published online 9 November 2026. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov, phase 3 trials of survodutide, registry records read on 15 November 2026 (LIVERAGE NCT06632444, LIVERAGE-Cirrhosis NCT06632457, SYNCHRONIZE-START NCT07855900, SYNCHRONIZE-HERA NCT07850050). clinicaltrials.gov
- FDA, PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027. www.fda.gov
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026, read on 15 November 2026. www.fda.gov
- FDA, Drugs@FDA and the openFDA drugsfda dataset: no record for survodutide, searched on 15 November 2026. www.accessdata.fda.gov
